Sanofi appoints two new Members to the Executive Committee to lead the new Commercial Organization

PR Newswire/Les Echos/ 
PRESS RELEASE 
 Sanofi appoints two new Members to the Executive Committee to lead the new 
                         Commercial Organization 
Paris, France - May 2, 2013 - Sanofi (EURONEXT: SAN and NYSE: SNY) announced
today a new commercial organization to better align with its business
priorities. The past four years have seen a significant shift within the company
to become an integrated global healthcare leader focused on patients' needs with
increasingly diversified businesses. The new organization and subsequent
appointments will be effective July 1st, 2013, following the previously
announced retirement of Hanspeter Spek, President, Global Operations. 
Two new units will be created, Global Commercial Operations and Global Divisions
& Strategic Commercial Development to replace the former Global Operations.
Peter Guenter, currently Senior Vice President, Europe, Sanofi, will be
appointed Executive Vice President, Global Commercial Operations. Pascale Witz,
currently President & Chief Executive Officer of Medical Diagnostics at GE
Healthcare, will join Sanofi and be appointed Executive Vice President, Global
Divisions & Strategic Commercial Development. Peter and Pascale will join the
Executive Committee. 
Christopher A. Viehbacher, Chief Executive Officer of Sanofi, declared:
"The appointment of these two new leaders will enable us to strengthen our
growth platforms and ensure the success of our new products to deliver a
sustainable future for our company. Peter is a proven leader with a strong track
record in achieving ambitious commercial objectives. His most recent experience
in Europe has prepared him well for driving growth in the rapidly evolving
healthcare environment. Pascale's diversified experience in healthcare and acute
commercial focus will be a great addition to Sanofi. I am confident that her
expertise in diagnostics and medical technology will rein force our mission as
an integrated global healthcare company." 
As Executive Vice President, Global Commercial Operations, Peter Guenter will
focus on in-market execution across the diverse regions of North America, Latin
America, Europe, Asia, Japan & Pacific and Intercontinental. The new commercial
operations organization and Peter's appointment will enable the regions to focus
on driving growth platforms and delivering innovative solutions to meet
patients' needs. 
As Executive Vice President, Global Divisions & Strategic Commercial
Development, Pascale Witz will be responsible for setting the strategic
direction and guiding product development of the Group key businesses. She will
have direct responsibilities for the Diabetes, Oncology & PCS (Pharmaceutical
Customer Solution) divisions, as well as a new structure for consumer
healthcare. As continued innovation and further development of our product
portfolio are our priorities, she will work in close collaboration with R&D, to
shape the profiles of new products and ensure the successful launch preparation.
The implementation of new integrated health solutions, part of the 'Beyond the
Pill' strategy, will be initiated from this organization. 
Biography of Peter Guenter
Peter Guenter is currently Senior Vice President, Europe, appointed in July
2011. In his current position, Peter is in charge of over 30 country entities
generating sales of over 7 billion Euros and employing over 9,000 people. Peter
has been instrumental in successfully transforming Sanofi in Europe over the
last 2 years. Throughout his career to date, which spans more than 25 years in
the pharmaceutical industry, his strategic acumen and strong capabilities in
leading countries have made him excellent in driving businesses in varied and
challenging macro-economic environments. 
Peter joined the Group in 1995 and held various positions in Belgium, France,
Europe and Global Marketing, where, in particular, he has been instrumental for
the worldwide success of Stilnox /Ambien and drove the development of Ambien CR.
In 2000, he was appointed General Manager, Belgium. He continued to quickly rise
through the group taking increasing responsibilities within the European
organization and became Vice President for Eastern Europe, where he oversaw the
European Union integration process of 10 countries who joined the EU in May
2004. After the acquisition of Aventis in 2005, Peter was appointed Vice
President, Northern Europe and led the integration between Sanofi and Aventis in
10 countries. In 2008, he was appointed General Manager, Commercial Operations
for Germany, where he transformed the affiliate in anticipation of the loss of
patent of Plavix and Taxotere. In early 2011, he took up the position of Head of
Multi-Country Organization for Germany, Austria and Switzerland, before being
appointed Senior Vice President, Europe in July 2011. 
Peter started his career as a sales representative for SmithKline in 1986, and
held a number of positions in marketing in Ciba Geigy and Parke Davis, before
joining Sanofi in 1995 as Business Unit Director CNS/Urology in the Belgian
affiliate. 
Peter is Belgian and holds a Master's Degree in Physical Education from the
Faculty of Medicine and Health Sciences of Ghent University, Belgium. He speaks
Dutch, German, English and French fluently. 
Biography of Pascale Witz
Pascale Witz has been President & Chief Executive Officer of Medical Diagnostics
at GE Healthcare since 2009. Based in the UK, it is a $2 billion plus leader in
pharmaceutical and molecular diagnostics, used by physicians in the early
detection, diagnosis, and management of disease. 
Pascale started her career in a research lab before moving to marketing at
Becton Dickinson France in 1991. She joined GE Healthcare in 1996 as Product
Manager for the vascular business in France. Over the years, she rose up through
the company and developed a successful international career within GE in Europe,
Africa, Middle East and the US, working and leading many of GE businesses. Prior
to taking up the position of President & CEO of the medical diagnostics
business, she was VP & General Manager for the Global Interventional Business
for France and US (2008-2009). 
Throughout her career within GEHC, Pascale Witz headed up a number of
businesses. She was General Manager, Computed Tomography (2006-2007), VP Sales &
Marketing Services (2005-2006), General Manager, Nuclear Medicine & PET
(2002-2004), VP Information Technology and VP Six Sigma and Quality (2000-2001). 
Pascale is French and holds a Master's degree in life sciences / molecular
biology from Institut National des Sciences Appliquées Lyon and an MBA from
INSEAD. 
About Sanofi
Sanofi, an integrated global healthcare leader, discovers, develops and
distributes therapeutic solutions focused on patients' needs. Sanofi has core
strengths in the field of healthcare with seven growth platforms: diabetes
solutions, human vaccines, innovative drugs, consumer healthcare, emerging
markets, animal health and the new Genzyme. Sanofi is listed in Paris (EURONEXT:
SAN) and in New York (NYSE: SNY). 
Forward Looking Statements
This press release contains forward-looking statements as defined in the Private
Securities Litigation Reform Act of 1995, as amended. Forward-looking statements
are statements that are not historical facts. These statements include
projections and estimates and their underlying assumptions, statements regarding
plans, objectives, intentions and expectations with respect to future financial
results, events, operations, services, product development and potential, and
statements regarding future performance. Forward-looking statements are
generally identified by the words "expects", "anticipates", "believes",
"intends", "estimates", "plans" and similar expressions. Although Sanofi's
management believes that the expectations reflected in such forward-looking
statements are reasonable, investors are cautioned that forward-looking
information and statements are subject to various risks and uncertainties, many
of which are difficult to predict and generally beyond the control of Sanofi,
that could cause actual results and developments to differ materially from those
expressed in, or implied or projected by, the forward-looking information and
statements. These risks and uncertainties include among other things, the
uncertainties inherent in research and development, future clinical data and
analysis, including post marketing, decisions by regulatory authorities, such as
the FDA or the EMA, regarding whether and when to approve any drug, device or
biological application that may be filed for any such product candidates as well
as their decisions regarding labelling and other matters that could affect the
availability or commercial potential of such product candidates, the absence of
guarantee that the product candidates if approved will be commercially
successful, the future appro val and commercial success of therapeutic
alternatives, the Group's ability to benefit from external growth opportunities,
trends in exchange rates and prevailing interest rates, the impact of cost
containment policies and subsequent changes thereto, the average number of
shares outstanding as well as those discussed or identified in the public
filings with the SEC and the AMF made by Sanofi, including those listed under
"Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements"
in Sanofi's annual report on Form 20-F for the year ended December 31, 2012.
Other than as required by applicable law, Sanofi does not undertake any
obligation to update or revise any forward-looking information or statements. 
Contacts:
Media Relations                 Investor Relations
Jean-Marc Podvin                Sébastien Martel
Tel.: + (33) 1 53 77 46 46      Tel.: + (33) 1 53 77 45 45
mr@sanofi.com                   ir@sanofi.com  
Composition of the Executive Committee, effective 1st July 2013 
Christopher A. Viehbacher
* Chief Executive Officer
* Chairman of Genzyme 
Olivier Charmeil
* Member ofthe Executive Committee and the Global Leadership Team
* Executive Vice President, Vaccines 
Jérôme Contamine
* Member of the Executive Committee and the Global Leadership Team
* Executive Vice President, Chief Financial Officer 
David-Alexandre Gros
* Member of the Executive Committee and the Global Leadership Team
* Executive Vice President, Chief Strategy Officer 
Peter Guenter
* Member of the Executive Committee and the Global Leadership Team
* Executive Vice President, Global Commercial Operations 
Karen Linehan
* Member ofthe Executive Committee and the Global Leadership Team
* Executive Vice President, Legal Affairs and General Counsel 
Philippe Luscan
* Member ofthe Executive Committee and the Global Leadership Team
* Executive Vice President, Industrial Affairs 
Roberto Pucci
* Member ofthe Executive Committee and the Global Leadership Team
* Executive Vice President, Human Resources 
Pascale Witz
* Member of the Executive Committee and the Global Leadership Team
* Executive Vice President, Global Divisions & Strategic Commercial Development 
Elias Zerhouni, MD
* Member ofthe Executive Committee and the Global Leadership Team
* President, Global R&D 
                  
The content and accuracy of news releases published on this site and/or 
distributed by PR Newswire or its partners are the sole responsibility of the 
originating company or organisation. Whilst every effort is made to ensure the 
accuracy of our services, such releases are not actively monitored or reviewed 
by PR Newswire or its partners and under no circumstances shall PR Newswire or 
its partners be liable for any loss or damage resulting from the use of such 
information. All information should be checked prior to publication. 
-0- May/02/2013 09:16 GMT